缺血性卒中发病率、致死率、致残率高，为全球公共卫生问题。回医药是民族医药的重要组成部分，有其独特的理论体系。《回回药方》是研究回医药的最直接蓝本，其对缺血性卒中治疗有详细记载。本研究提出"炎症因子、细胞凋亡Mcl-1/Noxa通路蛋白/基因表达和特异性代谢标志物是缺血性卒中的生物学基础" 的假说。 本项目选择《回回药方》中能体现回医理论的木香油方为研究对象，拟采用新生大鼠海马神经元缺氧-复氧损伤模型、MCAO法复制大鼠脑缺血再灌注损伤模型，从炎症损伤相关因子（TNF-α、TGF-β、IL-1、IL-6、IL-4和IL-10）、细胞凋亡蛋白（Bax、Bak、Bcl-2、Bcl-xL、Mcl-1、Noxa、Caspase9/3/7）和内源代谢标志物三个方面，采用免疫组化、Western blot、RT-PCR与代谢组学技术，探索缺血性卒中的生物学基础，揭示回药木香油方防治缺血性卒中的科学内涵。

Ischemic stroke is the most common disease and is associated with high mortality and morbidity, has seriously threatened the public health. Hui medicine is an important part of the national medicine, with its unique theoretical system. "HuiHui prescription" is the direct original version on Hui medicine research, which documented the treatment of ischemic stroke in detail, Mu Xiangyou prescription is the most representative prescription.In this study, the hypothesis "inflammatory factors 、expression of Mcl-1/Noxa pathway and specific metabolic markers may be biological foundation of ischemic stroke" was put forward. The model of newborn rat hippocampal neurons after hypoxia - reoxygenation injury and focal cerebral ischemia and reperfusion by MCAO to be used. The methods.of immunohistochemistry、Western blot 、RT-PCR and metabolomics technology will be used to test the inflammatory factors(TNF-α、TGF-β、IL-1、IL-6、IL-4 and IL-10)、 apoptosis factors（Bax、Bak、Bcl-2、Bcl-Xl、Mcl-1、Noxa、Caspase9、 Caspase 3 and Caspase 7） and metabolic markers. To reveal biological foundation of ischemic stroke and intervention of Hui medicine Mu Xiangyou prescription.